A recent systematic review of 315 studies looked at the effectiveness and adverse events of a range of treatments to prevent fractures. Their findings indicate strong evidence for the efficacy of a number of bisphosphonates. The magnitude of the effect indicated a NNT of between 40 and 89 over 1-3 years of treatment to prevent one fracture in women. The FLEX trial looked at the legacy effect of alendronate for patients who had been treated in the FIT trial for 5 years. They found that there was no difference in non-vertebral fracture risk in patients who continued alendronate for a further 5 years, compared to those that took a placebo for the five years. There was however an increase in the number of clinical vertebral fractures in patients who took placebo instead of alendronate (23/437, 5.3%) vs 16/662, 2.4% respectively; NNT 34 for one vertebral fracture over 5 years.

The same authors reanalysed the data later to look more closely at those patients with nonvertebral fractures. They clarified that in those patients without a previous vertebral fracture and with a T score of -2.5 or less when they had completed 5 years of alendronate treatment, that there was a benefit in fracture risk reduction (14.7% vs 28%, NNT 7 over 5 years) compared to no benefit in those patients with a T score of -2.5 or above.
Bisphosphonates are poorly absorbed (less than 5% bioavailable) and as such require relatively strict administration procedures. It is recommended that patients do not lie down for 30min after taking the agent and that it be taken at least an hour before the first food or beverage of the day. They are highly irritant to the oesophageal mucosa and can cause a range of upper abdominal and gastrointestinal symptoms (abdominal pain ~ 7%, acid dyspepsia, regurgitation and nausea (all ~ 4%).

Long term use has been associated with an increased risk of atypical fractures. A report of a Nationwide study of bisphosphonate use in Sweden indicated a markedly increased relative risk of fracture of the femoral shaft in both women (RR 55; 95% CI 39-79) and men (RR 54; 95% CI 15-192), with the risk increasing with duration of use. The absolute risk remained low (11 per 10,000 years of patient use; NNH 909) and the risk decreased rapidly (by 70% per year) after cessation of bisphosphonate.

Bisphosphonate associated osteonecrosis of the jaw (ONJ) is a rare, but serious clinical condition caused by anti-osteoclastic, anti-angiogenic and anti-human endothelial cell proliferation effects of bisphosphonates, which inhibit bone turnover. ONJ more often develops in those patients who are receiving either long-term nitrogen containing IV bisphosphonate therapy alone or have associated invasive dental procedures. Incidence is difficult to ascertain with one of the major drug companies estimating an incidence rate of 0.7 per 100,000 patients (0.0007%) for oral therapy. Estimates of 0.001% to 0.01% have been proposed by other authors (NNH of 1000-10,000).

FACTORS TO CONSIDER

IN FAVOUR OF DEPRESCRIBING

- **LOW RISK OF FALLS/IMMOBILITY**
  If patients have a low risk of falls, there may no longer be ongoing benefit to fracture risk reduction. Indeed if the reduced falls risk is due to prolonged immobility, even the requirement to sit upright to administer the oral bisphosphonate may be sufficient reason to reconsider the therapy.

- **NO PREVIOUS VERTEBRAL FRACTURES AND 5 YEARS OR MORE OF TREATMENT**
  In patients with only non-vertebral fractures, there seems to be little ongoing benefit of bisphosphonates in the 5 years after an initial 5 years of treatment, particularly if their T score is above -2.5 at the end of the first 5 years.

AGAINST DEPRESCRIBING

- **HIGH FRACTURE RISK (LOW T SCORE, HIGH FALLS RISK, STEROIDS ETC.)**
  Patients with a higher risk of fractures such as those with a very low T score (-2.5 or below) may have ongoing fracture risk reduction benefit from treatment with a bisphosphonate or another antiresorption agent.

DISCONTINUATION SYNDROMES

Bisphosphonates can be stopped abruptly without the need for tapering.
REFERENCES